The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel
Open accessAbstract
: There is abundant evidence that the risk of atherosclerotic vascular disease is directly related to plasma cholesterol levels. Accordingly, all of the national and transnational screening and therapeutic guidelines are based on total or LDL cholesterol. This presumes that cholesterol is the most important lipoprotein‐related proatherogenic risk variable. On the contrary, risk appears to be more directly related to the number of circulating atherogenic particles that contact and enter the arterial wall than to the measured concentration of cholesterol in these lipoprotein fractions. Each of the atherogenic lipoprotein particles contains a single molecule of apolipoprotein (apo) B and therefore the concentration of apo B provides a direct measure of the number of circulating atherogenic lipoproteins. Evidence from fundamental, epidemiological and clinical trial studies indicates that apo B is superior to any of the cholesterol indices to recognize those at increased risk of vascular disease and to judge the adequacy of lipid‐lowering therapy. On the basis of this evidence, we believe that apo B should be included in all guidelines as an indicator of cardiovascular risk. In addition, the present target adopted by the Canadian guideline groups of an apo B <90 mg dL−1 in high‐risk patients should be reassessed in the light of the new clinical trial results and a new ultra‐low target of <80 mg dL−1 be considered. The evidence also indicates that the apo B/apo A‐I ratio is superior to any of the conventional cholesterol ratios in patients without symptomatic vascular disease or diabetes to evaluate the lipoprotein‐related risk of vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
De Backer, G. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00347-6 · Cited by 2,251
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Serum Cholesterol, Lipoproteins, and the Risk of Coronary Heart Disease: The Framingham Study
KANNEL, W. B., CASTELLI, W. P., GORDON, T., & MCNAMARA, P. M. (1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-1 · Cited by 2,057
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Walldius, G., Jungner, I., Holme, I., Aastveit, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,229
Self-citationStampfer, M. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110036029 · Cited by 1,079
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Self-citationClinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Feinman, R. D., Pogozelski, W. K., Astrup, A., Bernstein, R. K., Fine, E. J., Westman, E. C., Accurso, A., Frassetto, L., Gower, B. A., McFarlane, S. I., et al. (2015) · Nutrition · doi:10.1016/j.nut.2014.06.011 · Cited by 912
“These include apolipoprotein (apo) B [71], ratio of total cholesterol to HDL, higher populations of the smaller dense LDL known as pattern B [72,73], as well as the ratio of apoB to apoA1.”
McQueen, M. J., Hawken, S., Wang, X., Ounpuu, S., Sniderman, A., Probstfield, J., Steyn, K., Sanderson, J. E., Hasani, M., Volkova, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61076-4 · Cited by 864
Self-citationGenest, J., McPherson, R., Frohlich, J., Anderson, T., Campbell, N., Carpentier, A., Couture, P., Dufour, R., Fodor, G., Francis, G. A., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70715-9 · Cited by 768
Self-citationLipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention
Munoz (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6269 · Cited by 760
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 707
Self-citationSniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659
Self-citationIngelsson, E., Schaefer, E. J., Contois, J. H., McNamara, J. R., Sullivan, L., Keyes, M. J., Pencina, M. J., Schoonmaker, C., Wilson, P. W. F., D’Agostino, R. B., et al. (2007) · JAMA · doi:10.1001/jama.298.7.776 · Cited by 608
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
WALLDIUS, G., & JUNGNER, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01643.x · Cited by 583
Self-citationJellinger, P. S., Smith, D. A., Mehta, A. E., Ganda, O., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.034 · Cited by 529
Self-citationMcKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 514
Self-citationMora, S., Otvos, J. D., Rifai, N., Rosenson, R. S., Buring, J. E., & Ridker, P. M. (2009) · Circulation · doi:10.1161/circulationaha.108.816181 · Cited by 490
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
“Table 1 AACE Lipid Targets for Patients with Type 2 Diabetes (188,189,197,200,240-251)”
BackgroundCromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., Sullivan, L., Vasan, R. S., Wilson, P. W. F., & D’Agostino, R. B. (2007) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2007.10.001 · Cited by 425
Carbohydrate Restriction has a More Favorable Impact on the Metabolic Syndrome than a Low Fat Diet
Volek, J. S., Phinney, S. D., Forsythe, C. E., Quann, E. E., Wood, R. J., Puglisi, M. J., Kraemer, W. J., Bibus, D. M., Fernandez, M. L., & Feinman, R. D. (2009) · Lipids · doi:10.1007/s11745-008-3274-2 · Cited by 397
The Role of Triglycerides in Atherosclerosis
Talayero, B. G., & Sacks, F. M. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0220-3 · Cited by 355
Grundy, S. M. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 347
Beyond Low-Density Lipoprotein Cholesterol
Arsenault, B. J., Rana, J. S., Stroes, E. S. G., Després, J.-P., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K.-T. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.057 · Cited by 342
Grundy, S. M., Arai, H., Barter, P., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A., Davidson, M. H., Genest, J., Kesäniemi, Y. A., et al. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 327
Self-citationContois, J. H., McConnell, J. P., Sethi, A. A., Csako, G., Devaraj, S., Hoefner, D. M., & Warnick, G. R. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.118356 · Cited by 326
Athinarayanan, S. J., Adams, R. N., Hallberg, S. J., McKenzie, A. L., Bhanpuri, N. H., Campbell, W. W., Volek, J. S., Phinney, S. D., & McCarter, J. P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00348 · Cited by 324
McPherson, R., Frohlich, J., Fodor, G., & Genest, J. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70310-5 · Cited by 308
Self-citationStein, E. A., Dufour, R., Gagne, C., Gaudet, D., East, C., Donovan, J. M., Chin, W., Tribble, D. L., & McGowan, M. (2012) · Circulation · doi:10.1161/circulationaha.112.104125 · Cited by 301
Self-citationGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“Patients with diabetes, therefore, can be classified as high risk, very-high risk, or extreme risk; as such, the AACE recommends LDL-C targets of <100 mg/dL, <70 mg/dL, and <55 mg/dL; non-HDL-C targets of <130 mg/ dL, <100 mg/dL, and <80 mg/dL; and apo B targets of <90 mg/dL, <80 mg/dL, and 70 mg/dL, respectively, wit…”
BackgroundEvaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
(2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 276
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 270
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260
Self-citationLanglois, M. R., Chapman, M. J., Cobbaert, C., Mora, S., Remaley, A. T., Ros, E., Watts, G. F., Borén, J., Baum, H., Bruckert, E., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.287037 · Cited by 260
Self-citationAccurso, A., Bernstein, R. K., Dahlqvist, A., Draznin, B., Feinman, R. D., Fine, E. J., Gleed, A., Jacobs, D. B., Larson, G., Lustig, R. H., et al. (2008) · Nutrition & Metabolism · doi:10.1186/1743-7075-5-9 · Cited by 263
“An increase in apolipoprotein B (apoB) may be a preferred marker since each atherogenic lipoprotein particle contains one molecule of apoB; total LDL would bias results towards lower risk [39].”
BackgroundKones, R. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 259
Mora, S., Buring, J. E., & Ridker, P. M. (2014) · Circulation · doi:10.1161/circulationaha.113.005873 · Cited by 255
Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2020-0490 · Cited by 248
Self-citationThe LDL to HDL Cholesterol Ratio as a Valuable Tool to Evaluate Coronary Heart Disease Risk
Fernandez, M. L., & Webb, D. (2008) · Journal of the American College of Nutrition · doi:10.1080/07315724.2008.10719668 · Cited by 255
El Harchaoui, K., van der Steeg, W. A., Stroes, E. S. G., Kuivenhoven, J. A., Otvos, J. D., Wareham, N. J., Hutten, B. A., Kastelein, J. J. P., Khaw, K.-T., & Boekholdt, S. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.043 · Cited by 239
“In fact, data upporting LDL-P as an alternative treatment target has ained support from clinical intervention studies showing hat on-treatment levels of apoB or NMR-measured DL-P were more reliable indicators of residual CAD risk han on-treatment LDL-C (2,4,5,18,19).”
BackgroundResultInfluentialEffect of Omega-3 Dosage on Cardiovascular Outcomes
Bernasconi, A. A., Wiest, M. M., Lavie, C. J., Milani, R. V., & Laukkanen, J. A. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.08.034 · Cited by 237
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
“total apoB (30) levels are often increased along with the atherogenic dyslipidemia complex.”
BackgroundBhanpuri, N. H., Hallberg, S. J., Williams, P. T., McKenzie, A. L., Ballard, K. D., Campbell, W. W., McCarter, J. P., Phinney, S. D., & Volek, J. S. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0698-8 · Cited by 190
Tay, J., Brinkworth, G. D., Noakes, M., Keogh, J., & Clifton, P. M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.08.050 · Cited by 190
Wilkins, J. T., Li, R. C., Sniderman, A., Chan, C., & Lloyd-Jones, D. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.055 · Cited by 181
Self-citationPencina, M. J., D’Agostino, R. B., Zdrojewski, T., Williams, K., Thanassoulis, G., Furberg, C. D., Peterson, E. D., Vasan, R. S., & Sniderman, A. D. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315569411 · Cited by 164
“Yet others propose that apoB, which measures the number of atherogenic particles, may be the most accurate quantifier of cardiovascular risk attributable to the atherogenic lipoproteins.(2) In selecting which lipid markers best quantify risk it should be recognized that these markers are highly correlated with each ot…”
BackgroundSelf-citationBeyond Low-Density Lipoprotein Cholesterol
Mudd, J. O., Borlaug, B. A., Johnston, P. V., Kral, B. G., Rouf, R., Blumenthal, R. S., & Kwiterovich, P. O. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.045 · Cited by 136
Self-citationMora, S., Caulfield, M. P., Wohlgemuth, J., Chen, Z., Superko, H. R., Rowland, C. M., Glynn, R. J., Ridker, P. M., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016857 · Cited by 126
“It has been hypothesized that some of this increased risk is due to high particle concentrations (numbers) of LDL (LDL-p), other atherogenic lipoproteins (very-low-density lipoprotein [VLDL] particles and intermediate-density lipoprotein [IDL]), or their subfractions and that risk resulting from these particles may no…”
BackgroundSelf-citationContois, J. H., Warnick, G. R., & Sniderman, A. D. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.05.004 · Cited by 123
Self-citationStalenhoef, A. F., & de Graaf, J. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328304b63c · Cited by 121
Self-citationHolme, I., Aastveit, A. H., Jungner, I., & Walldius, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01925.x · Cited by 106
Self-citationMiller, M., Ginsberg, H. N., & Schaefer, E. J. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.11.046 · Cited by 102
on behalf of the FIELD study investigators, Taskinen, M.-R., Barter, P. J., Ehnholm, C., Sullivan, D. R., Mann, K., Simes, J., Best, J. D., Hamwood, S., & Keech, A. C. (2010) · Diabetologia · doi:10.1007/s00125-010-1806-9 · Cited by 94
Self-citationCharlton-Menys, V., Betteridge, D. J., Colhoun, H., Fuller, J., France, M., Hitman, G. A., Livingstone, S. J., Neil, H. A. W., Newman, C. B., Szarek, M., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.111401 · Cited by 94
Self-citationAdvanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use
Mora, S. (2009) · Circulation · doi:10.1161/circulationaha.108.819359 · Cited by 89
A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.
de Graaf, J., Couture, P., & Sniderman, A. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0982 · Cited by 80
Self-citationMancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.019 · Cited by 70
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
“directly measure circulating atherogenic lipoproteins than LDL cholesterol.(110,113) ApoB has analytic and biological sta-”
BackgroundMartin, S. S., Qasim, A. N., Mehta, N. N., Wolfe, M., Terembula, K., Schwartz, S., Iqbal, N., Schutta, M., Bagheri, R., & Reilly, M. P. (2009) · Diabetes · doi:10.2337/db08-1794 · Cited by 60
Guay, V., Lamarche, B., Charest, A., Tremblay, A. J., & Couture, P. (2012) · Metabolism · doi:10.1016/j.metabol.2011.06.002 · Cited by 48
“[8] Barter PJ, Ballantyne CM, Carmena R, et al.”
BackgroundSelf-citationLi, N., Li, Q., Tian, X.-Q., Qian, H.-Y., & Yang, Y.-J. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0077-0 · Cited by 45
“Apolipoprotein B (ApoB), which is produced in the liver, is an essential component of LDL-C and all other atherogenic lipoproteins [5, 6].”
Backgroundvan den Berg, M. J., van der Graaf, Y., de Borst, G. J., Kappelle, L. J., Nathoe, H. M., Visseren, F. L. J., van Petersen, R., van Dinther, B. G. F., Algra, A., van der Graaf, Y., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.06.048 · Cited by 39
Lorenzatti, A. J., Monsalvo, M. L., López, J. A. G., Wang, H., & Rosenson, R. S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01287-6 · Cited by 34
Self-citationGrundy, S. M., Vega, G. L., Tomassini, J. E., & Tershakovec, A. M. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.003 · Cited by 33
Bays, H. E., & Ballantyne, C. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283325083 · Cited by 29
Self-citationKim, C.-W., Hong, S., Chang, Y., Lee, J. A., Shin, H., & Ryu, S. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-0692 · Cited by 25
Hisamatsu, T., Fujiyoshi, A., Miura, K., Ohkubo, T., Kadota, A., Kadowaki, S., Kadowaki, T., Yamamoto, T., Miyagawa, N., Zaid, M., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.07.019 · Cited by 24
Metadata
- Authors
- BARTER, P. J., BALLANTYNE, C. M., CARMENA, R., CABEZAS, M. C., CHAPMAN, M. J., COUTURE, P., DE GRAAF, J., DURRINGTON, P. N., FAERGEMAN, O., FROHLICH, J., FURBERG, C. D., GAGNE, C., HAFFNER, S. M., HUMPHRIES, S. E., JUNGNER, I., KRAUSS, R. M., KWITEROVICH, P., MARCOVINA, S., PACKARD, C. J., PEARSON, T. A., REDDY, K. S., ROSENSON, R., SARRAFZADEGAN, N., SNIDERMAN, A. D., STALENHOEF, A. F., STEIN, E., TALMUD, P. J., TONKIN, A. M., WALLDIUS, G., & WILLIAMS, K. M. S.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2006-02-10
- Volume
- 259
- Issue
- 3
- Pages
- 247-258
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2045054080
- Cited by
- 464
- References
- 105
- FWCI
- 44.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.